Absci up on cancer drug deal with AstraZeneca

** Shares of artificial intelligence (AI) biologics firm
Absci  ABSI.O  rise ~10% to $1.91 premarket 
    ** Company said on Sunday it has signed a deal worth up to
$247 mln with  AstraZeneca  AZN.L  to design a cancer-fighting
antibody    
    ** The deal aims for a zero-shot generative AI model
designed to create new and improved antibody therapeutics - ABSI
    ** ABSI did not say what kind of cancer it plans to target
    ** The company applies generative AI to design optimal drug
candidates based on target affinity, safety, manufacturability
and other traits
    ** Up to last close, ABSI shares down 17.1% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))

Recent news on AbSci

See all news